Study reveals hidden blood risk in common arthritis drugs
NCT ID NCT07237906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of 122 adults who took TNF-α inhibitors (drugs for rheumatoid arthritis and similar conditions) to find out how often they developed neutropenia—a drop in infection-fighting white blood cells. Researchers looked at blood test results and patient histories to determine the frequency, severity, and risk factors for this side effect. The goal was to better understand the real-world impact of these widely used medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUTROPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istanbul University - Cerrahpasa (IUC)
Istanbul, 34098, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Rare disease drug shows promise in reducing infections
- New antibiotic could shield blood cancer patients from deadly infections
- Can a single drug boost blood counts and delay cancer in High-Risk patients?